These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 1422962

  • 21. Acute effects of nasal salmon calcitonin on calcium and bone metabolism.
    Thamsborg G, Skousgaard SG, Daugaard H, Schifter S, Kollerup G, Sørensen OH.
    Calcif Tissue Int; 1993 Oct; 53(4):232-6. PubMed ID: 8275350
    [Abstract] [Full Text] [Related]

  • 22. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
    Tolino A, Romano L, Ronsini S, Riccio S, Montemagno U.
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
    [Abstract] [Full Text] [Related]

  • 23. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
    Cecchettin M, Bellometti S, Cremonesi G, Solimeno LP, Torri G.
    Biomed Pharmacother; 1995 Jul; 49(10):465-8. PubMed ID: 8746073
    [Abstract] [Full Text] [Related]

  • 24. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
    Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C.
    J Clin Invest; 1988 Oct; 82(4):1268-74. PubMed ID: 3262626
    [Abstract] [Full Text] [Related]

  • 25. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 26. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study.
    Ljunghall S, Gärdsell P, Johnell O, Larsson K, Lindh E, Obrant K, Sernbo I.
    Calcif Tissue Int; 1991 Jul; 49(1):17-9. PubMed ID: 1893291
    [Abstract] [Full Text] [Related]

  • 27. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
    Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R.
    Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
    [Abstract] [Full Text] [Related]

  • 28. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
    Tekeoğlu I, Adak B, Budancamanak M, Demirel A, Ediz L.
    Rheumatol Int; 2005 Dec; 26(2):157-61. PubMed ID: 15660234
    [Abstract] [Full Text] [Related]

  • 29. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormley GJ, Melton ME.
    J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
    [Abstract] [Full Text] [Related]

  • 30. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX, Li H.
    Chin Med J (Engl); 2008 Jul 20; 121(14):1280-4. PubMed ID: 18713548
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
    Stĕpán J, Formánková J, Masatová A, Michalský M, Rosenová Z.
    Cas Lek Cesk; 1997 Apr 16; 136(8):242-8. PubMed ID: 9264868
    [Abstract] [Full Text] [Related]

  • 34. [Effect of low calcitonin doses on bone remodeling in postmenopausal women with high bone turnover rate].
    Campusano C, López JM, Campino C, Cárdenas I, Rojas A.
    Rev Med Chil; 2000 Apr 16; 128(4):387-91. PubMed ID: 10962855
    [Abstract] [Full Text] [Related]

  • 35. Is heritability a risk factor for postmenopausal osteoporosis?
    Hansen MA, Hassager C, Jensen SB, Christiansen C.
    J Bone Miner Res; 1992 Sep 16; 7(9):1037-43. PubMed ID: 1414496
    [Abstract] [Full Text] [Related]

  • 36. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
    Reginster JY, Denis D, Deroisy R, Lecart MP, De Longueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P.
    J Bone Miner Res; 1994 Jan 16; 9(1):69-73. PubMed ID: 8154311
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Decreased serum osteocalcin levels in patients with postmenopausal osteoporosis.
    Pietschmann P, Resch H, Krexner E, Woloszczuk W, Willvonseder R.
    Acta Med Austriaca; 1991 Jan 16; 18(5):114-6. PubMed ID: 1796722
    [Abstract] [Full Text] [Related]

  • 39. Acute effect of the intranasal administration of salmon calcitonin in osteoporotic women.
    Vega E, Gonzalez D, Ghiringhelli G, Mautalen C.
    Bone Miner; 1989 Nov 16; 7(3):267-73. PubMed ID: 2611446
    [Abstract] [Full Text] [Related]

  • 40. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
    Overgaard K, Hansen MA, Jensen SB, Christiansen C.
    BMJ; 1992 Sep 05; 305(6853):556-61. PubMed ID: 1393035
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.